Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Two-Part Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0941 and the Effect of Food and Proton Pump Inhibition on GDC-0941 Tablet Pharmacokinetics in Healthy Volunteers.

Next Previous
Trial Profile

An Open-Label, Two-Part Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0941 and the Effect of Food and Proton Pump Inhibition on GDC-0941 Tablet Pharmacokinetics in Healthy Volunteers.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pictrelisib (Primary) ; Rabeprazole
  • Indications Breast cancer; Duodenal ulcer; Gastric ulcer; Gastro-oesophageal reflux; Helicobacter infections; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Peptic ulcer; Solid tumours; Zollinger-Ellison syndrome
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Genentech

Most Recent Events

  • 27 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 24 Feb 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
  • 11 Feb 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top